Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
    • Erlebnisraum Bioökonomie
    • Innovation & Startups

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Gene regulation - 20/07/2021 Vor schwarzem Hintergrund ist ein gelb leuchtendes Chromosom zwischen blau gefärbten Chromosomen sichtbar.

    The many faces of the epigenetic regulator MOF

    Epigenetic modifications play a crucial role in coordinated gene transcription, and are required for a fertilised egg cell to be able to develop into an organism with different cell types. Dr. Asifa Akhtar from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg has been studying the essential epigenetic regulator protein MOF for 20 years.

    https://www.gesundheitsindustrie-bw.de/en/article/news/die-vielen-gesichter-des-epigenetischen-regulators-mof
  • Optogenetic cell analysis - 15/05/2023 A young woman at a desk with long brown curls can be seen looking friendly into the camera.

    opto biolabs: how frustration and inventiveness led to the establishment of a company

    When she found she had no suitable illumination devices for her doctoral thesis, Dr. Kathrin Brenker simply created her own customised adapters and founded a company called opto biolabs. Now, Brenker and company co-founder Luis Köbele sell two different types of devices. The main goal is to equip laboratories with illumination technologies that allow optogenetics methods to be used to accelerate development of optogenetic therapeutics.

    https://www.gesundheitsindustrie-bw.de/en/article/news/opto-biolabs-how-frustration-and-inventiveness-led-establishment-company
  • Press release - 20/12/2022

    New approach prevents rejection of transplanted organs

    Inhibition of a protein complex in cells of the immune system prevents rejection of transplanted organs – this has been shown in a study by immunologists from the University of Konstanz, the Biotechnology Institute Thurgau (BITg) and Chongqing Cancer University Hospital.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approach-prevents-rejection-transplanted-organs
  • Press release - 30/03/2022

    CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV

    CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-gsk-start-clinical-development-second-generation-covid-19-vaccine-candidate-cv2cov
  • Press release - 18/08/2022

    CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

    CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on mRNA, today announced the start of a Phase 1 study of the modified COVID-19 mRNA vaccine candidate CV0501, administered as a booster dose to previous COVID-19 vaccination. Developed in collaboration with GSK, CV0501 is based on CureVac’s second-generation mRNA backbone and is designed to specifically protect against the Omicron variant.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-starts-phase-1-clinical-study-modified-omicron-targeting-covid-19-vaccine-candidate
  • Dossier - 01/10/2012 virtual molecular structure

    Systems biology understanding complex biological systems

    Systems biology studies complex interactions within biological systems on the genome proteome and organelle level. Many techniques from the fields of systems theory and associated fields can be used to gain an understanding of the behaviour and biological mechanisms of cellular systems.

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/systems-biology-understanding-complex-biological-systems
  • Press release - 23/11/2021

    Multi-peptide vaccine against SARS-CoV-2 shows strong T-cell immune response

    At the University Hospital Tübingen, clinical evaluation of an in-house developed vaccine (CoVac-1) against SARS-CoV-2 was started in November 2020 under the direction of Prof. Dr. Juliane Walz in the CCU Translational Immunology of the Medical Clinic (Medical Director Prof. Dr. Helmut Salih). Now the results of the Phase I study are available and demonstrate a potent activation of the T-cell response against the coronavirus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/multi-peptide-vaccine-against-sars-cov-2-shows-strong-t-cell-immune-response
  • Article - 22/03/2019 Prof. Lichter (left) and Prof. Schneeweiss, who run the Translational Breast Cancer Programme in Heidelberg, in the laboratory

    Personalised therapies for treating metastasing breast cancer

    Breast cancer is characterised by broad genetic diversity. Successful treatment is made even more difficult by the fact that, in advanced breast cancer, the properties of metastases often differ significantly from the primary tumour. The Heidelberg CATCH study is now collecting genetic profiles from patients' metastasis tissue samples, which can be used to tailor therapy to individual requirements.

    https://www.gesundheitsindustrie-bw.de/en/article/news/personalisierte-therapieansaetze-bei-metastasiertem-brustkrebs
  • Press release - 12/05/2022

    New imaging method makes tiny medical robots visible in the body

    Microrobots have the potential to revolutionize medicine. Researchers at the Max Planck ETH Centre for Learning Systems have now developed an imaging technique that for the first time recognises cell-sized microrobots individually and at high resolution in a living organism. This is an important step towards precise control of the robots and their clinical translation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-imaging-method-makes-tiny-medical-robots-visible-body
  • Press release - 24/04/2023

    Hidden RNA repair mechanism discovered in humans

    Konstanz researchers discover the function of a previously unexplored protein: In three characteristic steps, "C12orf29" links the ends of RNA strands. Proteins that perform this kind of RNA ligation were previously unknown in humans. The results of the study suggest that it is important for RNA repair during cellular stress.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/hidden-rna-repair-mechanism-discovered-humans
  • Press release - 06/02/2023

    Fewer side effects thanks to personalised medicine

    Patients have 30 percent fewer serious side effects when medication doses are tailored to their genetic profile. This is what an international research consortium has found out, including the Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology at the Bosch Health Campus. With an individual DNA medication pass, as used in the study, treatments can be made more effective and safer in the future.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/weniger-nebenwirkungen-dank-personalisierter-medizin
  • Press release - 28/04/2022

    Tumors on withdrawal: Amino acid deficiency shrinks childhood tumors

    Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tumors-withdrawal-amino-acid-deficiency-shrinks-childhood-tumors
  • Press release - 04/10/2023

    Therapeutic option for tumor patients with the rare DNAJB1-PRKACA gene fusion

    A phase I clinical trial is now starting at Tuebingen University Hospital in the Clinical Collaboration Unit (CCU) Translational Immunology, in collaboration with the Department of Internal Medicine I, which is investigating the therapeutic cancer peptide vaccine Fusion-VAC-XS15 in combination with immune checkpoint blockade by atezolizumab (Tecentriq®).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapeutic-option-tumor-patients-rare-dnajb1-prkaca-gene-fusion
  • Press release - 07/10/2021

    First comprehensive atlas of neuron types in the brain published

    International research collaboration explores the properties of different neuron types in the brain motor cortex of mice, monkeys and humans using novel experimental and data analysis techniques.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/first-comprehensive-atlas-neuron-types-brain-published
  • Press release - 08/02/2022

    New European Research Council grant for Max Plack Researcher

    The European Research Council is funding a large-scale proof-of-concept study on a new genome sequencing method called “Haplotagging”. Haplotagging is a new method for sequencing our genome with superior quality and faster speed, developed by group leader Frank Chan and his team at the Friedrich Miescher Laboratory at the Max Planck Campus, Tübingen, Germany.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-european-research-council-grant-max-plack-researcher
  • Press release - 11/01/2023

    Newly discovered surface structures may affect immune function

    Using new microscopic methods in combination with machine learning-based image analysis, researchers from Freiburg have discovered new structures on the surface of living B cells that affect the distribution and possibly the function of their antigen receptors. The researchers' study has been published in The EMBO Journal.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/newly-discovered-surface-structures-may-affect-immune-function
  • Press release - 25/05/2023

    Oops, did I do that – or is there someone else in my head?

    Tübingen researchers describe connection between action and feeling of authorship - finding sheds light on delusions of external control in schizophrenia

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/oops-did-i-do-or-there-someone-else-my-head
  • Press release - 30/08/2021

    CureVac Preclinical Data Demonstrates Significant Reduction of Liver Fibrosis with mRNA Therapeutic

    CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the publication entitled “Therapeutic HNF4A mRNA attenuates liver fibrosis in a preclinical model” in the peer-reviewed Journal of Hepatology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-preclinical-data-demonstrates-significant-reduction-liver-fibrosis-mrna-therapeutic
  • Press release - 03/03/2022

    Identifying Alzheimer's risks – as early as 17 years before diagnosis

    In order to develop approaches for the prevention and treatment of Alzheimer's dementia in clinical trials, it would be helpful to be able to identify people with a particularly high risk of developing the disease. But which biomarkers can indicate an increased likelihood of disease early on in symptom-free people who actually develop Alzheimer's later?

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/identifying-alzheimers-risks-early-17-years-diagnosis
  • Press release - 20/01/2023

    Czech Inventor Award for Martina Benešová-Schäfer

    With the "Česká Hlava" awards, the Czech government has been honoring the country's most brilliant minds every year since 2002 and recognizing exceptional achievements in research, development and innovation. Martina Benešová-Schäfer of the German Cancer Research Center was among the six laureates honored in 2022 at Charles University in Prague.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tschechischer-erfinderpreis-fuer-martina-benesova-schaefer
  • Press release - 27/10/2021

    Disordered brain activity in Rolandic epilepsy can be influenced by brief sounds during sleep

    Rolandic epilepsy is a common form of epilepsy in children which occurs primarily during sleep. Short sounds played during sleep can partially suppress the neuronal discharges characteristic of epilepsy. That’s according to a research team from the University of Tübingen and Tübingen University Hospitals. The team is headed by Dr. Hong-Viet Ngo and Professor Jan Born from the Institute of Medical Psychology and Behavioral Neurobiology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/disordered-brain-activity-rolandic-epilepsy-can-be-influenced-brief-sounds-during-sleep
  • Press release - 13/10/2021

    Tackling the collateral damage from antibiotics

    EMBL scientists pave the way for reducing the harmful side effects antibiotics have on gut bacteria. Antibiotics help us to treat bacterial infections and save millions of lives each year. But they can also harm the helpful microbes residing in our gut, weakening one of our body’s first lines of defence against pathogens and compromising the multiple beneficial effects our microbiota has for our health.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tackling-collateral-damage-antibiotics
  • Press release - 18/11/2021

    Overcoming resistance to cancer treatment: bone and soft tissue tumors in adolescents as a model system

    Treatment resistance is a central problem in the treatment of cancer. Bone and soft tissue tumors – known as sarcomas – in adolescents and young adults often stop responding to treatment too. This is because cancer cells develop a large number of new characteristics as the disease progresses and often become resistant to drugs that were originally effective.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-resistance-cancer-treatment-bone-and-soft-tissue-tumors-adolescents-model-system
  • Press release - 18/03/2022

    Lung Tissue from the Lab

    Laboratory studies of lung tissue usually require the removal of large amounts of human or animal tissue. Now scientists from the University of Freiburg’s Faculty of Medicine have succeeded in collaboration with American researchers in generating tiny quantities of lung tissue, so-called organoids, from just a few body cells in the lab.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/lung-tissue-lab
  • Press release - 05/06/2023

    New findings about human metabolic processes

    Researchers at the Faculty of Medicine at the University of Freiburg have gained significant new insights into metabolic processes in the kidney. The scientists from the Institute of Genetic Epidemiology at the Medical Center - University of Freiburg measured tiny molecules, so-called metabolites, which occur in blood and urine and reflect our metabolism, in samples from more than 5,000 study participants.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-findings-about-human-metabolic-processes

Page 2 / 8

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
    • Erlebnisraum Bioökonomie
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search